A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
2016
Cancer Discovery
FGFR1 and FGFR2 are amplified in many tumour types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial we show that gastric cancers with high-level clonal FGFR2 amplification have a high response rate to the selective FGFR inhibitor AZD4547, whilst cancers with sub-clonal or low-level amplification did not respond. Using cell lines and patient derived xenografts models, we show high-level FGFR2 amplification initiates a distinct
doi:10.1158/2159-8290.cd-15-1246
pmid:27179038
pmcid:PMC5338732
fatcat:razilydc4jclnfu5p4t62lnnbm